BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32942118)

  • 1. Inflammatory colitis associated with Teriflunomide.
    Esfahani NZ; von Geldern G; Romba MC; Parikh DA; Wundes A
    Mult Scler Relat Disord; 2020 Nov; 46():102480. PubMed ID: 32942118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Son M; McEwan L; Ubaidat M; Bovell K; Morrow SA
    Mult Scler; 2020 Nov; 26(13):1801-1803. PubMed ID: 32031458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.
    Landais A; Alhendi R; Gouverneur A; Teron-Aboud B
    Mult Scler Relat Disord; 2017 Oct; 17():92-94. PubMed ID: 29055483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teeth loss after teriflunomide treatment: Casual or causal? A short case series.
    Vacchiano V; Frattaruolo N; Mancinelli L; Foschi M; Carotenuto A; Scandellari C; Piattelli M; Brescia Morra V; Lugaresi A
    Mult Scler Relat Disord; 2018 Aug; 24():120-122. PubMed ID: 29982109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digestive side-effects with teriflunomide: Thoughts on lactose.
    Lebrun C; Bertagna M; Bresch S; Cohen M
    Rev Neurol (Paris); 2018 Dec; 174(10):722-725. PubMed ID: 30409479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide, a potential novel cause of chronic active colitis.
    Kővári B; Zachs J; Murchie B; Lauwers GY
    Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888
    [No Abstract]   [Full Text] [Related]  

  • 8. Palmar pustular psoriasis associated with teriflunomide treatment.
    Negrotto L; Correale J
    Mult Scler Relat Disord; 2019 Jan; 27():400-402. PubMed ID: 30513502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Camara-Lemarroy CR; Castilló J; Sastre-Garriga J; Tintore M; Montalban X
    Mult Scler; 2018 Sep; 24(10):1383-1385. PubMed ID: 29473796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
    Gerschenfeld G; Servy A; Valeyrie-Allanore L; de Prost N; Cecchini J
    Mult Scler; 2015 Oct; 21(11):1476-7. PubMed ID: 26199352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
    Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
    Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
    Chan A; de Seze J; Comabella M
    CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ▼Teriflunomide for multiple sclerosis.
    Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    Yamout BI; Said M; Hannoun S; Zeineddine M; Massouh J; Khoury SJ
    J Neurol Sci; 2017 Sep; 380():79-81. PubMed ID: 28870594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
    Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
    Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
    Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
    Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.